


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/58	A2	(11) International Publication Number: WO 00/66129 (43) International Publication Date: 9 November 2000 (09.11.00)
<p>(21) International Application Number: PCT/EP00/03747</p> <p>(22) International Filing Date: 25 April 2000 (25.04.00)</p> <p>(30) Priority Data: 99201390.4 29 April 1999 (29.04.99) EP</p> <p>(71) Applicant (for all designated States except US): AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 AB Arnhem (NL).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): COELINGH BENNINK, Herman, Jan, Tijmen [NL/NL]; Melvill van Cambeelaan 38, NL-3971 BE Driebergen (NL). DECKERS, Godefridus, Hermanus, Johanna [NL/NL]; van Limburg Stirumstraat 34, NL-5344 HW Oss (NL). DOLS, Paul, Peter, Marie, Antonius [NL/NL]; Ringelenburg 1, NL-5346 VR Oss (NL). OR-LEMANS, Everardus, Otto, Maria [NL/NL]; Wolfespoor 12, NL-5343 XM Oss (NL). SCHOONEN, Wilhelmus, Gerardus, Eduardus, Joseph [NL/NL]; Parklaan 16, NL-5345 BV Oss (NL).</p> <p>(74) Agent: KRAAK, Hajo; P.O. Box 20, NL-5340 BH Oss (NL).</p>	<p>(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>	
<p>(54) Title: USE OF ANTIPROGESTAGENS IN COMBINED THERAPY</p> <div style="text-align: center;">  <p>(I)</p> </div> <p>(57) Abstract</p> <p>It has been found that the compound satisfying structural formula (I) has a surprisingly good suitability for being administered intermittently. This particular compound therewith has the highly advantageous property that it can be used in the specific medical application of combined therapy with progestagen-only preparations.</p>		